Fulltext

Antipsychotic drugs: is more worse? a meta-analysis of the published randomized control trials

Bollini, P. ; Pampallona, S. ; Orza, M. J. ; Adams, M. E. ; Chalmers, T. C.

In: Psychological Medicine, 1994, vol. 24, no. 2, p. 307-316

Ajouter à la liste personnelle
    Titre
    • Antipsychotic drugs: is more worse? a meta-analysis of the published randomized control trials
    Auteur
    • Bollini, P.. Technology Assessment Group, Harvard School of Public Health, Boston, MA., USA
    • Pampallona, S.. Technology Assessment Group, Harvard School of Public Health, Boston, MA., USA
    • Orza, M. J.. Technology Assessment Group, Harvard School of Public Health, Boston, MA., USA
    • Adams, M. E.. Technology Assessment Group, Harvard School of Public Health, Boston, MA., USA
    • Chalmers, T. C.. Technology Assessment Group, Harvard School of Public Health, Boston, MA., USA
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Psychological Medicine, 1994, vol. 24, no. 2, p. 307-316. Cambridge University Press
    Autre version électronique
    Classification
    • Santé
    Identifiant OAI-PMH
    • oai:doc.rero.ch:299569
    Summary
    Effectiveness and side-effects of high- versus low-dose neuroleptic treatment of chronic psychosis have been assessed through a meta-analysis of 22 published randomized control trials comparing different neuroleptic doses. No incremental clinical improvement was found at doses above 375 mg equivalent of chlorpromazine, while a significant increase in adverse reactions was observed